Clinical Research Directory
Browse clinical research sites, groups, and studies.
SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors
Sponsor: British Columbia Cancer Agency
Summary
The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer. Secondary objectives will be overall survival, progression-free survival and time to switch of next line of systemic therapy. Radiation-related adverse events will be assess, with a specific focus on dermatitis, lymphedema and brachial plexopathy. The exploratory objective is to correlate toxicities and outcomes with peripheral blood biomarkers and circulating tumor DNA to potentially help predict responses in future patients receiving combined therapy.
Official title: A Phase II Trial Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors (SABR-PRIMeR)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-07-01
Completion Date
2030-07-30
Last Updated
2025-04-24
Healthy Volunteers
No
Conditions
Interventions
SABR
Prescription dose/fractionation: 26Gy/5 with 40Gy/5 +/- 35Gy/5 Boost Radiation Technique: VMAT Treatment Frequency: Every other day (EOD)
Locations (1)
BC Cancer - Vancouver
Vancouver, British Columbia, Canada